GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lipidor AB (FRA:L7R) » Definitions » Cash-to-Debt

Lipidor AB (FRA:L7R) Cash-to-Debt : No Debt (1) (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lipidor AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lipidor AB's cash to debt ratio for the quarter that ended in Dec. 2024 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lipidor AB could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Lipidor AB's Cash-to-Debt or its related term are showing as below:

FRA:L7R' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.2   Med: No Debt   Max: No Debt
Current: 19.46

During the past 8 years, Lipidor AB's highest Cash to Debt Ratio was No Debt. The lowest was 1.20. And the median was No Debt.

FRA:L7R's Cash-to-Debt is ranked better than
79.7% of 1015 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs FRA:L7R: 19.46

Lipidor AB Cash-to-Debt Historical Data

The historical data trend for Lipidor AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lipidor AB Cash-to-Debt Chart

Lipidor AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial No Debt No Debt No Debt 1.19 No Debt

Lipidor AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.55 1.19 0.65 No Debt No Debt

Competitive Comparison of Lipidor AB's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Lipidor AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipidor AB's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lipidor AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lipidor AB's Cash-to-Debt falls into.


;
;

Lipidor AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lipidor AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Lipidor AB had no debt (1).

Lipidor AB's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Lipidor AB had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipidor AB  (FRA:L7R) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Lipidor AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lipidor AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipidor AB Business Description

Traded in Other Exchanges
Address
c/o Ekonomistubben AB, Box 55931, Stockholm, SWE, 102 16
Lipidor AB is a pharmaceutical development company with a pipeline of drug development projects in the preclinical and clinical phases. The company develops drugs for the treatment of skin diseases such as psoriasis, bacterial skin infections, and atopic dermatitis.

Lipidor AB Headlines

No Headlines